Skip to main content
Caplight Logo









Disperazol Pharma ApS

Disperazol Pharma ApS

Private
HumlebækHealthcare & Life Scienceshttps://www.disperazolpharma.com/

Last Round

Grant

Jun 5, 2023

Total Funding Raised

$10,800

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Disperazol Pharma ApS is a biotechnology company that develops non-traditional antimicrobial compounds designed to dismantle biofilms of Gram-negative pathogens to enhance the efficacy of existing antibiotics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

AMRantimicrobial resistancebiofilm dispersalantibiotic resistancebacterial biofilmsGram-negative pathogenssuperbug treatmentc-di-GMP signalingdrug discoverybiotech R&Dantibiotic adjuvantphosphodiesterase activationbiotech spinout

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Disperazol Pharma ApS Comparables

Compare Disperazol Pharma ApS with similar companies based on industry and business-model similarity.

Disperazol Pharma ApS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioTryp Therapeutics
85%
Resistia
82%
HHV Biotech
80%

Disperazol Pharma ApS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 5, 2023

Disperazol Pharma ApS Investors

Notable investors and investment history

Disperazol Pharma ApS investors
InvestorRounds
INCATEGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors grew 416% MoM, from 251 to 1.3K.

  • Jun 5, 2023

    $11K grant received from INCATE.

Disperazol Pharma ApS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Disperazol Pharma ApS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Disperazol Pharma ApS's valuation, stock price, and market status.

Firmographic Details

HeadquartersHumlebæk
Employee Range1
Year Founded2023
Last FundingJun 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?